Immunologically augmented cancer treatment using modern radiotherapy.
暂无分享,去创建一个
[1] Colin G Orton,et al. The linear-quadratic model is inappropriate to model high dose per fraction effects in radiosurgery. , 2009, Medical physics.
[2] Kohei Miyazono,et al. TGFβ signalling: a complex web in cancer progression , 2010, Nature Reviews Cancer.
[3] T. Quinn,et al. Melanoma therapy via peptide-targeted {alpha}-radiation. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.
[4] M. Karin,et al. Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. , 2010, Cytokine & growth factor reviews.
[5] D. Hallahan,et al. Radiation induces an antitumour immune response to mouse melanoma , 2009, International journal of radiation biology.
[6] C. Drake. Prostate cancer as a model for tumour immunotherapy , 2010, Nature Reviews Immunology.
[7] T. Teshima,et al. Particle irradiation suppresses metastatic potential of cancer cells. , 2005, Cancer research.
[8] Laurence Zitvogel,et al. Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy , 2007, Nature Medicine.
[9] R. Schreiber,et al. Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion , 2011, Science.
[10] Young-Soo Hong,et al. Geldanamycin inhibits TGF-beta signaling through induction of Hsp70. , 2010, Archives of biochemistry and biophysics.
[11] R. Figlin,et al. Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. , 2009, Cancer research.
[12] D. Gabrilovich,et al. Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. , 2011, Trends in immunology.
[13] S. Ghosh,et al. NF-κB and the immune response , 2006, Oncogene.
[14] Jiayuh Lin,et al. The novel curcumin analog FLLL32 decreases STAT3 DNA binding activity and expression, and induces apoptosis in osteosarcoma cell lines , 2011, BMC Cancer.
[15] M. Karin,et al. Immunity, Inflammation, and Cancer , 2010, Cell.
[16] N. Kawashima,et al. Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti–CTLA-4 Antibody , 2009, Clinical Cancer Research.
[17] B. Hann,et al. TGFβ1 Inhibition Increases the Radiosensitivity of Breast Cancer Cells In Vitro and Promotes Tumor Control by Radiation In Vivo , 2011, Clinical Cancer Research.
[18] W. Zimmermann,et al. Combination immunotherapy and active-specific tumor cell vaccination augments anti-cancer immunity in a mouse model of gastric cancer , 2011, Journal of Translational Medicine.
[19] P. Okunieff,et al. The biological basis of a comprehensive grading system for the adverse effects of cancer treatment. , 2003, Seminars in radiation oncology.
[20] L. V. van Kempen,et al. Reactive oxygen species in melanoma and its therapeutic implications , 2007, Melanoma research.
[21] O. Inanami,et al. Ionizing radiation induces mitochondrial reactive oxygen species production accompanied by upregulation of mitochondrial electron transport chain function and mitochondrial content under control of the cell cycle checkpoint. , 2012, Free radical biology & medicine.
[22] L. Dubois,et al. [18F]EF3 is not superior to [18F]FMISO for PET-based hypoxia evaluation as measured in a rat rhabdomyosarcoma tumour model , 2009, European Journal of Nuclear Medicine and Molecular Imaging.
[23] Michael Scholz,et al. Quantification of the relative biological effectiveness for ion beam radiotherapy: direct experimental comparison of proton and carbon ion beams and a novel approach for treatment planning. , 2010, International journal of radiation oncology, biology, physics.
[24] Mary Helen Barcellos-Hoff,et al. Radiation and the microenvironment – tumorigenesis and therapy , 2005, Nature Reviews Cancer.
[25] T. Teshima,et al. Carbon ion irradiation suppresses metastatic potential of human non-small cell lung cancer A549 cells through the phosphatidylinositol-3-kinase/Akt signaling pathway. , 2011, Journal of radiation research.
[26] H. Yoshikawa,et al. Establishment and characterization of a murine osteosarcoma cell line (LM8) with high metastatic potential to the lung , 1998, International journal of cancer.
[27] U. Cortes,et al. STAT3 is essential for the maintenance of neurosphere‐initiating tumor cells in patients with glioblastomas: A potential for targeted therapy? , 2011, International journal of cancer.
[28] P. Scherle,et al. Developing c-MET pathway inhibitors for cancer therapy: progress and challenges. , 2010, Trends in molecular medicine.
[29] C. Hunter,et al. Identifying Mechanisms for Therapeutic Intervention in Chordoma: c-Met Oncoprotein , 2008, Spine.
[30] Zhigang Tian,et al. Defining the critical hurdles in cancer immunotherapy , 2011, Journal of Translational Medicine.
[31] Marco Durante,et al. Assessing the risk of second malignancies after modern radiotherapy , 2011, Nature Reviews Cancer.
[32] V. Zoete,et al. Rational design of 4-aryl-1,2,3-triazoles for indoleamine 2,3-dioxygenase 1 inhibition. , 2012, Journal of medicinal chemistry.
[33] B. Nelson,et al. Standard Treatments Induce Antigen-Specific Immune Responses in Prostate Cancer , 2007, Clinical Cancer Research.
[34] B. Suarez-Alvarez,et al. The NKG2D receptor: sensing stressed cells. , 2008, Trends in molecular medicine.
[35] M. Mihm,et al. CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS , 2008, Nature Clinical Practice Oncology.
[36] S. Pestka,et al. Chemotherapeutics and Radiation Stimulate MHC Class I Expression through Elevated Interferon-beta Signaling in Breast Cancer Cells , 2012, PloS one.
[37] G. Fuller,et al. Inhibition of p-STAT3 Enhances IFN-α Efficacy against Metastatic Melanoma in a Murine Model , 2010, Clinical Cancer Research.
[38] Mark W. Dewhirst,et al. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response , 2008, Nature Reviews Cancer.
[39] S. Morad,et al. Ceramide-orchestrated signalling in cancer cells , 2012, Nature Reviews Cancer.
[40] L. Bubendorf,et al. High expression of indoleamine 2,3-dioxygenase gene in prostate cancer. , 2008, European journal of cancer.
[41] Y. Bang,et al. Phase II study of sunitinib as second-line treatment for advanced gastric cancer , 2010, Investigational New Drugs.
[42] H. Shirato,et al. Local radiation therapy inhibits tumor growth through the generation of tumor-specific CTL: its potentiation by combination with Th1 cell therapy. , 2010, Cancer research.
[43] M. Neuenhahn,et al. NF-κB Is a Negative Regulator of IL-1β Secretion as Revealed by Genetic and Pharmacological Inhibition of IKKβ , 2007, Cell.
[44] J. S. Rao,et al. Effects of irradiation on tumor cell survival, invasion and angiogenesis , 2010, Journal of Neuro-Oncology.
[45] Weiping Zou,et al. Immunosuppressive networks in the tumour environment and their therapeutic relevance , 2005, Nature Reviews Cancer.
[46] S. Rafii,et al. Low-dose irradiation promotes tissue revascularization through VEGF release from mast cells and MMP-9–mediated progenitor cell mobilization , 2005, The Journal of experimental medicine.
[47] R. Weichselbaum,et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. , 2009, Blood.
[48] Y. Yonemitsu,et al. Carbon‐ion beam treatment induces systemic antitumor immunity against murine squamous cell carcinoma , 2010, Cancer.
[49] T. Nheu,et al. Hyperactivation of Stat3 in gp130 mutant mice promotes gastric hyperproliferation and desensitizes TGF-β signaling , 2005, Nature Medicine.
[50] L. Coussens,et al. The Tumor-Immune Microenvironment and Response to Radiation Therapy , 2010, Journal of Mammary Gland Biology and Neoplasia.
[51] O. Witte,et al. PET probes for distinct metabolic pathways have different cell specificities during immune responses in mice. , 2010, The Journal of clinical investigation.
[52] G. Prendergast. Immunological thought in the mainstream of cancer research , 2012, Oncoimmunology.
[53] M. Kaag,et al. Endothelial Membrane Remodeling Is Obligate for Anti-Angiogenic Radiosensitization during Tumor Radiosurgery , 2010, PloS one.
[54] Y. Yamada,et al. High-dose, single-fraction image-guided intensity-modulated radiotherapy for metastatic spinal lesions. , 2008, International journal of radiation oncology, biology, physics.
[55] B. Pockaj,et al. Cyclooxygenase-2 Inhibitor Enhances the Efficacy of a Breast Cancer Vaccine: Role of IDO1 , 2006, The Journal of Immunology.
[56] Alberto Mantovani,et al. Neutrophils in the activation and regulation of innate and adaptive immunity , 2011, Nature Reviews Immunology.
[57] Abhishek D. Garg,et al. Immunogenic cell death and DAMPs in cancer therapy , 2012, Nature Reviews Cancer.
[58] Shuang Chen,et al. Transforming Growth Factor-β Differentially Inhibits MyD88-dependent, but Not TRAM- and TRIF-dependent, Lipopolysaccharide-induced TLR4 Signaling* , 2005, Journal of Biological Chemistry.
[59] J. Welsh,et al. The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells , 2009, Radiation oncology.
[60] G. Prendergast,et al. Towards a genetic definition of cancer-associated inflammation: role of the IDO pathway. , 2010, The American journal of pathology.
[61] Ute Wirkner,et al. Trimodal glioblastoma treatment consisting of concurrent radiotherapy, temozolomide, and the novel TGF-β receptor I kinase inhibitor LY2109761. , 2011, Neoplasia.
[62] K. Hunter,et al. Modeling metastasis in vivo. , 2004, Carcinogenesis.
[63] T. Bortfeld. IMRT: a review and preview , 2006, Physics in medicine and biology.
[64] K. Tracey,et al. HMGB1 as a cytokine and therapeutic target , 2002, Journal of endotoxin research.
[65] C. Sautès-Fridman,et al. The immune contexture in human tumours: impact on clinical outcome , 2012, Nature Reviews Cancer.
[66] Michael Dougan,et al. Immune therapy for cancer. , 2009, Annual review of immunology.
[67] Eric Vivier,et al. Targeting natural killer cells and natural killer T cells in cancer , 2012, Nature Reviews Immunology.
[68] J. Castle,et al. Exploiting the mutanome for tumor vaccination. , 2012, Cancer research.
[69] D. Bigner,et al. Glioblastoma multiforme: a review of where we have been and where we are going , 2009, Expert opinion on investigational drugs.
[70] D. Roses,et al. Prospective assessment of optimal individual position (prone versus supine) for breast radiotherapy: volumetric and dosimetric correlations in 100 patients. , 2012, International journal of radiation oncology, biology, physics.
[71] K. Alitalo,et al. VEGF and angiopoietin signaling in tumor angiogenesis and metastasis. , 2011, Trends in molecular medicine.
[72] A. Odermatt,et al. Endoplasmic reticulum: reduced and oxidized glutathione revisited , 2013, Journal of Cell Science.
[73] R. Steinman,et al. Taking dendritic cells into medicine , 2007, Nature.
[74] J. Routy,et al. Human Activated T Lymphocytes Modulate IDO Expression in Tumors through Th1/Th2 Balance1 , 2009, The Journal of Immunology.
[75] Liang Shen,et al. The pharmacology of curcumin: is it the degradation products? , 2012, Trends in molecular medicine.
[76] Lech Papiez,et al. Universal survival curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapy. , 2008, International journal of radiation oncology, biology, physics.
[77] E. Proietti,et al. Exploitation of the propulsive force of chemotherapy for improving the response to cancer immunotherapy , 2012, Molecular oncology.
[78] M. Bernstein,et al. Combining radiation, immunotherapy, and antiangiogenesis agents in the management of cancer: the Three Musketeers or just another quixotic combination? , 2009, Molecular bioSystems.
[79] K. Yamaguchi,et al. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases. , 2009, Cancer research.
[80] C. Daniel,et al. Therapeutic opportunities for manipulating TReg cells in autoimmunity and cancer , 2012, Nature Reviews Drug Discovery.
[81] S. Haeryfar,et al. NKT cell costimulation: experimental progress and therapeutic promise. , 2011, Trends in molecular medicine.
[82] M. Weller,et al. Toll‐Like Receptor Engagement Enhances the Immunosuppressive Properties of Human Bone Marrow‐Derived Mesenchymal Stem Cells by Inducing Indoleamine‐2,3‐dioxygenase‐1 via Interferon‐β and Protein Kinase R , 2009, Stem cells.
[83] J. Wolchok,et al. The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation. , 2008, The oncologist.
[84] A. Evdokiou,et al. Zoledronic acid protects against osteosarcoma‐induced bone destruction but lacks efficacy against pulmonary metastases in a syngeneic rat model , 2010, International Journal of Cancer.
[85] K. Rock,et al. How dying cells alert the immune system to danger , 2008, Nature Reviews Immunology.
[86] G. V. Vande Woude,et al. Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer , 2009, Clinical Cancer Research.
[87] S. Demaria,et al. The convergence of radiation and immunogenic cell death signaling pathways , 2012, Front. Oncol..
[88] Qiang Xu,et al. Sensitization of human osteosarcoma cells to Vγ9Vδ2 T‐cell‐mediated cytotoxicity by zoledronate , 2012, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.
[89] E. Gore,et al. Stereotactic radiosurgery for the management of brain metastases. , 2010, The New England journal of medicine.
[90] Tak W. Mak,et al. Cytochrome c: functions beyond respiration , 2008, Nature Reviews Molecular Cell Biology.
[91] L. Zitvogel,et al. How to improve the immunogenicity of chemotherapy and radiotherapy , 2011, Cancer and Metastasis Reviews.
[92] E. Medico,et al. Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer. , 2011, Journal of the National Cancer Institute.
[93] C. V. van Noesel,et al. Radiation‐induced melanoma‐associated leucoderma, systemic antimelanoma immunity and disease‐free survival in a patient with advanced‐stage melanoma: a case report and immunological analysis , 2013, The British journal of dermatology.
[94] T. Hei,et al. Radiosensitization of melanoma cells through combined inhibition of protein regulators of cell survival , 2008, Apoptosis.
[95] H. Zhang,et al. STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients. , 2013, The Journal of clinical investigation.
[96] G. Dranoff,et al. Combining immunotherapy and targeted therapies in cancer treatment , 2012, Nature Reviews Cancer.
[97] A. Samii,et al. Expression of hepatocyte growth factor and c‐MET in skull base chordoma , 2008, Cancer.
[98] L. Zitvogel,et al. Chemotherapy and radiotherapy: cryptic anticancer vaccines. , 2010, Seminars in immunology.
[99] J. Pinilla-Ibarz,et al. Enhanced CD8 T cell cross-presentation by macrophages with targeted disruption of STAT3. , 2010, Immunology letters.
[100] A. Koong,et al. Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies. , 2010, International journal of radiation oncology, biology, physics.
[101] T. Nakano,et al. Application of carbon-ion beams or gamma-rays on primary tumors does not change the expression profiles of metastatic tumors in an in vivo murine model. , 2009, International journal of radiation oncology, biology, physics.
[102] D. Jaffray. Image-guided radiotherapy: from current concept to future perspectives , 2012, Nature Reviews Clinical Oncology.
[103] L. Pfeffer,et al. Curcumin Potentiates Rhabdomyosarcoma Radiosensitivity by Suppressing NF-κB Activity , 2013, PloS one.
[104] Laurence Zitvogel,et al. Immune parameters affecting the efficacy of chemotherapeutic regimens , 2011, Nature Reviews Clinical Oncology.
[105] M. Pecaut,et al. The impact of mouse strain on iron ion radio-immune response of leukocyte populations , 2010, International journal of radiation biology.
[106] W. Hong,et al. Targeting heat shock protein 90 overrides the resistance of lung cancer cells by blocking radiation-induced stabilization of hypoxia-inducible factor-1alpha. , 2009, Cancer research.
[107] M. Smyth,et al. Improving cancer immunotherapy by targeting tumor-induced immune suppression , 2011, Cancer and Metastasis Reviews.
[108] Hua Yu,et al. STATs in cancer inflammation and immunity: a leading role for STAT3 , 2009, Nature Reviews Cancer.
[109] Philippe Lambin,et al. How costly is particle therapy? Cost analysis of external beam radiotherapy with carbon-ions, protons and photons. , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[110] L. Marnett,et al. COX-2 Inhibitors Modulate IL-12 Signaling Through JAK-STAT Pathway Leading to Th1 Response in Experimental Allergic Encephalomyelitis , 2006, Journal of Clinical Immunology.
[111] A. Tefferi,et al. Abscopal effect in a patient with melanoma. , 2012, New England Journal of Medicine.
[112] S. Gerber,et al. Radiation-Induced IFN-γ Production within the Tumor Microenvironment Influences Antitumor Immunity1 , 2008, The Journal of Immunology.
[113] Kathryn D. Held,et al. Effects of low fluences of radiations found in space on cellular systems , 2009, International journal of radiation biology.
[114] E. Gragoudas,et al. Evidence-based estimates of outcome in patients irradiated for intraocular melanoma. , 2002, Archives of ophthalmology.
[115] Edouard I Azzam,et al. Ionizing radiation-induced metabolic oxidative stress and prolonged cell injury. , 2012, Cancer letters.
[116] K. Foley,et al. Phase I Evaluation of STA-1474, a Prodrug of the Novel HSP90 Inhibitor Ganetespib, in Dogs with Spontaneous Cancer , 2011, PloS one.
[117] T. Padhya,et al. HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment , 2010, The Journal of experimental medicine.
[118] X. Pivot,et al. Novel role for STAT3 in transcriptional regulation of NK immune cell targeting receptor MICA on cancer cells. , 2011, Cancer research.
[119] G. Riggins,et al. Molecular targeting of glioblastoma: Drug discovery and therapies. , 2011, Trends in molecular medicine.
[120] C. Lawton. Late outcomes following hypofractionated conformal radiotherapy vs. standard fractionation for localized prostate cancer: a nonrandomized contemporary comparison , 2010 .
[121] M. Durante,et al. Systematic analysis of RBE and related quantities using a database of cell survival experiments with ion beam irradiation , 2012, Journal of radiation research.
[122] C. Thiele,et al. Inhibition of STAT3 with orally active JAK inhibitor, AZD1480, decreases tumor growth in Neuroblastoma and Pediatric Sarcomas In vitro and In vivo , 2013, Oncotarget.
[123] Marco Durante,et al. Charged particles in radiation oncology , 2010, Nature Reviews Clinical Oncology.
[124] D. Gabrilovich,et al. Coordinated regulation of myeloid cells by tumours , 2012, Nature Reviews Immunology.
[125] T R Mackie,et al. History of tomotherapy , 2006, Physics in medicine and biology.
[126] C Bert,et al. Motion in radiotherapy: particle therapy , 2011, Physics in medicine and biology.
[127] S. Demaria,et al. Systemic effects of local radiotherapy. , 2009, The Lancet. Oncology.
[128] Sunil Krishnan,et al. Targeting inflammatory pathways for tumor radiosensitization. , 2010, Biochemical pharmacology.
[129] M. Karamouzis,et al. Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors. , 2009, The Lancet. Oncology.
[130] M. van den Broek,et al. Radiotherapy Promotes Tumor-Specific Effector CD8+ T Cells via Dendritic Cell Activation , 2012, The Journal of Immunology.
[131] F. Marincola,et al. Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma , 2011, Proceedings of the National Academy of Sciences.
[132] A. Haimovitz-Friedman,et al. Ceramide Biogenesis Is Required for Radiation-Induced Apoptosis in the Germ Line of C. elegans , 2008, Science.
[133] H. Tsujii,et al. Carbon ion radiotherapy for sacral chordoma. , 2011, The British journal of radiology.
[134] Laurence Zitvogel,et al. Immunogenic cell death in cancer therapy. , 2013, Annual review of immunology.
[135] F. Hassan,et al. Interleukin-10 inhibits tumor necrosis factor-α production in lipopolysaccharide-stimulated RAW 264.7 cells through reduced MyD88 expression , 2008, Innate immunity.
[136] N. Halama,et al. Seromic profiling of ovarian and pancreatic cancer , 2010, Proceedings of the National Academy of Sciences.
[137] C. E. Alvarez,et al. Dog models of naturally occurring cancer. , 2011, Trends in molecular medicine.
[138] M. McCarty. Minimizing the cancer-promotional activity of cox-2 as a central strategy in cancer prevention. , 2012, Medical hypotheses.
[139] M. Todaro,et al. Tumorigenic and metastatic activity of human thyroid cancer stem cells. , 2010, Cancer research.
[140] J. Higgins,et al. Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy , 2012, International journal of cancer.
[141] Axel Hoos,et al. Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria , 2009, Clinical Cancer Research.
[142] M. Weller,et al. Irradiation and hypoxia promote homing of haematopoietic progenitor cells towards gliomas by TGF-beta-dependent HIF-1alpha-mediated induction of CXCL12. , 2006, Brain : a journal of neurology.
[143] A. Mantovani,et al. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm , 2010, Nature Immunology.
[144] J. Talmadge,et al. Inflammatory cell infiltration of tumors: Jekyll or Hyde , 2007, Cancer and Metastasis Reviews.
[145] N. Kawashima,et al. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.
[146] F. Balkwill. Tumour necrosis factor and cancer , 2009, Nature Reviews Cancer.
[147] S. Ghosh,et al. Mitochondria in innate immune responses , 2011, Nature Reviews Immunology.
[148] M. Roizen,et al. Hallmarks of Cancer: The Next Generation , 2012 .
[149] K. Iwamoto,et al. Local irradiation of murine melanoma affects the development of tumour‐specific immunity , 2009, Immunology.
[150] R. Johnstone,et al. Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies. , 2012, Cancer research.
[151] John L. Meyer,et al. The expanding roles of stereotactic body radiation therapy and oligofractionation: toward a new practice of radiotherapy. , 2011, Frontiers of radiation therapy and oncology.
[152] S. Demaria,et al. Combining radiotherapy and cancer immunotherapy: a paradigm shift. , 2013, Journal of the National Cancer Institute.
[153] P. Vandenabeele,et al. A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death , 2012, The EMBO journal.
[154] A. Robles,et al. HSP90 inhibitor, DMAG, synergizes with radiation of lung cancer cells by interfering with base excision and ATM-mediated DNA repair , 2008, Molecular Cancer Therapeutics.
[155] Jian Jian Li,et al. NF-κB-mediated adaptive resistance to ionizing radiation , 2008 .
[156] R. Zlotecki,et al. Response to sunitinib in combination with proton beam radiation in a patient with chondrosarcoma: a case report , 2012, Journal of Medical Case Reports.
[157] Jedd D. Wolchok,et al. Immunologic correlates of the abscopal effect in a patient with melanoma. , 2012, The New England journal of medicine.
[158] L. Zitvogel,et al. The secret ally: immunostimulation by anticancer drugs , 2012, Nature Reviews Drug Discovery.
[159] K. Ohtomo,et al. Enhancement of Antitumor Radiation Efficacy and Consistent Induction of the Abscopal Effect in Mice by ECI301, an Active Variant of Macrophage Inflammatory Protein-1α , 2008, Clinical Cancer Research.
[160] James S Goydos,et al. Molecular analysis of melanoma-induced sentinel lymph node immune dysfunction , 2011, Cancer Immunology, Immunotherapy.
[161] S. Gool,et al. Experimental immunotherapy for malignant glioma: lessons from two decades of research in the GL261 model , 2011, Cancer Immunology, Immunotherapy.
[162] W. Lu,et al. Synergistic antitumor effect of TRAIL in combination with sunitinib in vitro and in vivo. , 2010, Cancer letters.
[163] R. Weichselbaum,et al. Blockade of tumor necrosis factor alpha signaling in tumor-associated macrophages as a radiosensitizing strategy. , 2010, Cancer research.
[164] Tadashi Kamada,et al. A Review of Update Clinical Results of Carbon Ion Radiotherapy , 2012, Japanese journal of clinical oncology.
[165] C. Mody,et al. Immunotherapy in gliomas: limitations and potential of natural killer (NK) cell therapy. , 2011, Trends in molecular medicine.
[166] J. Niederkorn. Ocular Immune Privilege and Ocular Melanoma: Parallel Universes or Immunological Plagiarism? , 2012, Front. Immun..
[167] P. Vandenabeele,et al. ER stress-induced inflammation: does it aid or impede disease progression? , 2012, Trends in molecular medicine.
[168] Kevin Camphausen,et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy , 2006 .
[169] Paul Kremer,et al. Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[170] Toshikazu Nakamura,et al. Hepatic gene expression of NK4, an HGF-antagonist/angiogenesis inhibitor, suppresses liver metastasis and invasive growth of colon cancer in mice , 2004, Cancer Gene Therapy.
[171] S. Korreman. Motion in radiotherapy: photon therapy , 2012, Physics in medicine and biology.
[172] Marco Durante,et al. Particle therapy for noncancer diseases. , 2012, Medical physics.
[173] N. Kawashima,et al. The Combination of Ionizing Radiation and Peripheral Vaccination Produces Long-term Survival of Mice Bearing Established Invasive GL261 Gliomas , 2006, Clinical Cancer Research.
[174] S. Demaria,et al. Radiation as an immunological adjuvant: current evidence on dose and fractionation , 2012, Front. Oncol..
[175] Oliver Jäkel,et al. Randomised phase I/II study to evaluate carbon ion radiotherapy versus fractionated stereotactic radiotherapy in patients with recurrent or progressive gliomas: The CINDERELLA trial , 2010, BMC Cancer.
[176] C. Melief. Cancer immunotherapy by dendritic cells. , 2008, Immunity.
[177] S. Demaria,et al. Up-regulation of the Pro-inflammatory Chemokine CXCL16 is a Common Response of Tumor Cells to Ionizing Radiation , 2010, Radiation research.
[178] Giuseppe Schettino,et al. New insights on cell death from radiation exposure. , 2005, The Lancet. Oncology.
[179] Simon C Watkins,et al. Sunitinib facilitates the activation and recruitment of therapeutic anti‐tumor immunity in concert with specific vaccination , 2011, International journal of cancer.
[180] Kou-Juey Wu,et al. TWIST activation by hypoxia inducible factor-1 (HIF-1): Implications in metastasis and development , 2008, Cell cycle.
[181] H. Moch,et al. γ-Radiation Promotes Immunological Recognition of Cancer Cells through Increased Expression of Cancer-Testis Antigens In Vitro and In Vivo , 2011, PloS one.
[182] P. Choong,et al. Osteosarcoma treatment: state of the art , 2009, Cancer and Metastasis Reviews.
[183] Sang-Gu Hwang,et al. Bcl‐XL and STAT3 mediate malignant actions of γ‐irradiation in lung cancer cells , 2010, Cancer science.
[184] J. Debus,et al. Blockade of TGF-beta signaling by the TGF β RI kinase Inhibitor LY 2109761 enhances radiation response and prolongs survival in glioblastoma , 2011 .
[185] E. Monti,et al. Rhabdomyosarcomas: an overview on the experimental animal models , 2012, Journal of cellular and molecular medicine.
[186] Roberto A. Maldonado,et al. How tolerogenic dendritic cells induce regulatory T cells. , 2010, Advances in immunology.
[187] Drew M. Pardoll,et al. The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.
[188] Dirk Verellen,et al. Innovations in image-guided radiotherapy , 2008, Nature Reviews Cancer.
[189] C. Drake,et al. Immunotherapy earns its spot in the ranks of cancer therapy , 2012, The Journal of experimental medicine.
[190] Te Vuong,et al. Past, present, and future of radiotherapy for the benefit of patients , 2013, Nature Reviews Clinical Oncology.
[191] Zvi Fuks,et al. Tumor Response to Radiotherapy Regulated by Endothelial Cell Apoptosis , 2003, Science.
[192] Marco Durante,et al. Charged particle therapy—optimization, challenges and future directions , 2013, Nature Reviews Clinical Oncology.
[193] S. Demaria,et al. Select forms of tumor cell apoptosis induce dendritic cell maturation , 2005, Journal of leukocyte biology.
[194] G. Multhoff,et al. Radiation-induced stress proteins - the role of heat shock proteins (HSP) in anti- tumor responses. , 2012, Current medicinal chemistry.
[195] Hua Yu,et al. Tumour immunology: Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment , 2007, Nature Reviews Immunology.
[196] Gerald McMahon,et al. SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. , 2003, Cancer research.
[197] A. Bozec,et al. Combination of sunitinib, cetuximab and irradiation in an orthotopic head and neck cancer model. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[198] E. Smit,et al. Design of clinical trials of radiation combined with antiangiogenic therapy. , 2007, The oncologist.
[199] Tohru Okada,et al. Carbon ion radiotherapy: clinical experiences at National Institute of Radiological Science (NIRS). , 2010, Journal of radiation research.
[200] S. Demaria,et al. Role of T lymphocytes in tumor response to radiotherapy , 2012, Front. Oncol..
[201] N. Kawashima,et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. , 2004, International journal of radiation oncology, biology, physics.
[202] P. van Endert,et al. Mechanisms of pre‐apoptotic calreticulin exposure in immunogenic cell death , 2009, The EMBO journal.
[203] R. Timmerman,et al. The Confluence of Stereotactic Ablative Radiotherapy and Tumor Immunology , 2011, Clinical & developmental immunology.
[204] Joe Y. Chang,et al. A Phase I Clinical Trial of Thoracic Radiotherapy and Concurrent Celecoxib for Patients with Unfavorable Performance Status Inoperable/Unresectable Non–Small Cell Lung Cancer , 2005, Clinical Cancer Research.
[205] T. Hei,et al. Suppression of the proinflammatory response of metastatic melanoma cells increases TRAIL‐induced apoptosis , 2011, Journal of cellular biochemistry.
[206] S. Cullen,et al. Granzymes in cancer and immunity , 2010, Cell Death and Differentiation.
[207] K. Stagliano,et al. Cutting Edge: Tumor-Specific CD8+ T Cells Infiltrating Prostatic Tumors Are Induced to Become Suppressor Cells1 , 2009, The Journal of Immunology.
[208] J. Berzofsky,et al. Transforming Growth Factor-β Production and Myeloid Cells Are an Effector Mechanism through Which CD1d-restricted T Cells Block Cytotoxic T Lymphocyte–mediated Tumor Immunosurveillance , 2003, The Journal of Experimental Medicine.
[209] H. Nagawa,et al. Circulating lymphocyte is an important determinant of the effectiveness of preoperative radiotherapy in advanced rectal cancer , 2011, BMC Cancer.
[210] L. Zitvogel,et al. Abscopal but desirable , 2012, Oncoimmunology.
[211] H. Matsui,et al. TGF-β and HGF transmit the signals through JNK-dependent Smad2/3 phosphorylation at the linker regions , 2004, Oncogene.
[212] Catrin Bauréus Koch,et al. Radiation Immunomodulatory Gene Tumor Therapy of Rats with Intracerebral Glioma Tumors , 2010, Radiation research.